What baseline and ongoing laboratory monitoring is recommended for a patient on Dilantin (phenytoin) therapy?

Phenytoin (Dilantin) Monitoring Guidelines

Baseline Laboratory Testing

Before initiating phenytoin therapy, obtain complete blood count (CBC) with differential, comprehensive metabolic panel including liver function tests (ALT, AST), renal function tests (BUN, creatinine), and urinalysis. 1

• Baseline testing identifies contraindications and establishes reference values for future comparison 2
• Pregnancy testing should be performed in women of childbearing potential, as phenytoin is Pregnancy Category D 1
• Consider baseline albumin level, as hypoalbuminemia significantly affects phenytoin protein binding and interpretation of total serum levels 3

Serum Phenytoin Level Monitoring

For clinically stable patients on long-term phenytoin maintenance therapy, measure serum phenytoin levels every 3-6 months. 4

Therapeutic Range and Interpretation

• The therapeutic total phenytoin concentration is 10-20 µg/mL (free phenytoin 1-2 µg/mL) 5, 6
• Some patients require concentrations >15 µg/mL for optimal seizure control, while others achieve control below 10 µg/mL—clinical response supersedes rigid adherence to reference ranges 6, 7
• In patients with hypoalbuminemia or renal failure, measure free (unbound) phenytoin levels, as total levels will be misleadingly low despite adequate free drug concentrations. 3

Timing of Level Checks

• After IV loading: check level 2-4 hours post-infusion to confirm therapeutic range achievement, then again at 12 hours (approximately 50% of patients have subtherapeutic levels at this timepoint) 5, 6
• After oral loading: levels typically reach therapeutic range within 3-8 hours 6
• With oral maintenance dosing (no loading): steady-state achieved in 3-7 days, though some patients may require 1-2 weeks 2, 8

Situations Requiring More Frequent Monitoring

Increase monitoring frequency to weekly or biweekly when:

• Drug interactions occur, particularly when adding or removing enzyme-inducing drugs (carbamazepine, phenobarbital) or enzyme-inhibiting drugs (valproic acid, fluoxetine, cimetidine) 4, 1
• Clinical signs of toxicity appear: nystagmus, ataxia, tremor, somnolence, cognitive impairment 4, 6
• Hepatic or renal disease develops, increasing risk of drug accumulation 4, 6
• Dose adjustments are made—phenytoin exhibits saturable (non-linear) kinetics, so small dose increases can produce disproportionately large increases in serum levels 9
• Patient is receiving enteral feeding preparations, which lower phenytoin absorption 1

Routine Laboratory Monitoring Beyond Drug Levels

Monitor CBC with differential, liver function tests, and renal function tests every 6-12 months in all patients on chronic phenytoin therapy. 2

• CBC monitoring detects rare but serious hematologic toxicity (leukopenia, thrombocytopenia) 1
• Liver function tests identify hepatotoxicity, which can impair phenytoin metabolism 1
• Urinalysis should be performed regularly to ensure safety 2
• Phenytoin may cause elevated glucose, alkaline phosphatase, and gamma-glutamyl transpeptidase (GGT); decreased T4 levels 1

Clinical Monitoring

At each visit (minimum twice yearly), perform:

• Physical examination focusing on neurologic signs (ataxia, nystagmus, tremor) and signs of liver disease 2
• Examination for Kayser-Fleischer rings if compliance is questioned—their appearance may indicate non-adherence 2
• Oral examination for gingival hyperplasia, a common chronic adverse effect 1
• Assessment for cutaneous changes, particularly in patients on long-term therapy 2
• Screening for psychiatric symptoms, especially depression and suicidal ideation 1

Critical Monitoring Pitfalls

• Never adjust phenytoin dosage based solely on total serum levels in patients with hypoalbuminemia, renal failure, or concurrent valproic acid therapy—these conditions alter protein binding and require free level measurement. 3
• Phenytoin exhibits zero-order (saturable) kinetics above certain concentrations, meaning small dose increases (e.g., 100 mg/day) can cause disproportionately large increases in serum levels and precipitate toxicity 9
• Generic formulation switches can cause bioavailability problems due to differences in particle size—monitor levels closely after any formulation change 9
• In critically ill patients, altered protein binding is common and free levels should be measured or calculated to avoid misinterpretation 3